&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-18, 22:07

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai
Danny Gaylord

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-07-10, 07:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal

Jillian Pearce

Popular Posts